SEC Form 4 · accession 0000059478-16-000339

Spyre Therapeutics, Inc. · SYRE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Apr 12, 2016

Accepted (ET)

Apr 14, 2016 · 6:41 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001636282

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Apr 12, 2016	C	2,010,924	$0.00	A	2,068,543	I	by fund
Common Stock^F2	Apr 12, 2016	P	500,000	$10.00	A	2,568,543	I	by fund

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F2,F1	$0.00	Apr 12, 2016	C	890,476	D	—	—	Common Stock	890,476	0	I
Series B Preferred Stock^F2,F1	$0.00	Apr 12, 2016	C	1,120,448	D	—	—	Common Stock	1,120,448	0	I

F1In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
F2These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.